View : 213 Download: 0
Long-term clinical outcomes and stent thrombosis of sirolimus-eluting versus bare metal stents in patients with end-stage renal disease: Results of Korean multicenter angioplasty team (KOMATE) registry: CORONARY ARTERY DISEASE
- Long-term clinical outcomes and stent thrombosis of sirolimus-eluting versus bare metal stents in patients with end-stage renal disease: Results of Korean multicenter angioplasty team (KOMATE) registry: CORONARY ARTERY DISEASE
- Kim B.-K.; Oh S.; Jeon D.W.; Yang J.Y.; Kim J.-S.; Park S.; Choi D.; Jang Y.; Hong B.-K.; Kwon H.M.; Lee S.-W.; Goh C.W.; Kwon K.; Ryu S.K.
- Ewha Authors
- SCOPUS Author ID
- Issue Date
- Journal Title
- Journal of Interventional Cardiology
- Journal of Interventional Cardiology vol. 22, no. 5, pp. 411 - 419
- SCIE; SCOPUS
- Document Type
Show the fulltext
- Background: There are still controversies about long-term clinical outcomes of sirolimus-eluting stents (SES) versus bare metal stents (BMS) implantation in patients with end-stage renal diseases (ESRD). Objective: To compare long-term outcomes in patients with (ESRD) following SES versus BMS implantation. Methods: Between March 2003 and July 2005, a total of 54 patients (80 lesions) with ESRD undergoing SES implantation [SES-ESRD] were enrolled and compared with 51 patients (54 lesions) with ESRD receiving BMS during the same periods [BMS-ESRD] in the Korean Multicenter Angioplasty Team Registry. The primary outcome was the composite of death, myocardial infarction (MI), or any stent thrombosis (ST) according to the Academic Research Consortium definition during a 3-year follow-up. Results: The cumulative 3-year rate of composite of death, MI, or ST of the SES-ESRD group (24%) was nearly similar with that of the BMS-ESRD group (24%, P = 1.000). The 3-year rates of death (26% vs. 24%, P = 0.824) or MACE (37% vs. 43%, P = 0.331) in the SES-ESRD did not differ significantly from those in the BMS-ESRD. However, the SES-ESRD showed a sustained lower 3-year TVR rate (9%), compared with BMS-ESRD (24%, P = 0.042). The rate of any ST in SES-ESRD was not significantly higher than that in the BMS-ESRD (17% vs. 14%, P = 0.788). There was no significant difference in the rate of late or very late ST between SES-ESRD (15%) versus BMS-ESRD group (10%, P = 0.557). Conclusions: SES did not increase the risks for death, MI, or any ST in patients with ESRD during the long-term follow-up, compared with BMS. (J Interven Cardiol 2009;22:411-419) © 2009, Wiley Periodicals, Inc.
- Appears in Collections:
- 의과대학 > 의학과 > Journal papers
- Files in This Item:
There are no files associated with this item.
- RIS (EndNote)
- XLS (Excel)
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.